Patent and Trademark Office for its patent application covering the use of benzamides and nicotinamides for the treatment of inflammatory diseases involving NF-kB and apoptosis.
Nasdaq: OXGN; SSE) announced today that it has entered into a research collaboration with Active Biotech(A) (SSE: ACTI B) to explore the use of OXiGENE's benzamide and nicotinamide technology in the treatment of inflammatory diseases.
Nordenvall, President and CEO of OXiGENE commented, "This patent application bolsters OXiGENE's proprietary position and underscores our benzamide
core technology, enabling the Company to simultaneously develop anti-tumor and anti-inflammatory indications within the same drug delivery program.
MIP-1145 is one of a family of proprietary, small molecule benzamide
compounds that target melanin, a naturally-occurring pigment that is overexpressed in approximately 40 percent of melanomas.
This provides further validation for our approach to using these compounds to enhance the efficacy of traditional cancer treatments, and introduce a novel anti-inflammatory role for the benzamides
In more than two years of research of the benzamides
, Active has not only developed a great deal of expertise but have also demonstrated the potential for these compounds in a number of disease areas.
Although classified as a N-substituted benzamide
and, therefore, covered by OXiGENE's use patent for all N-substituted benzamides
as sensitizers for chemotherapy and radiation, Oxi-104 is not based on metoclopramide like Sensamide(TM) and Neu-Sensamide(TM).
Separately, OXiGENE also received notice from The European Patent Office and the Israel Patent Office that the corresponding European and Israeli patents covering the use of Sensimide(TM) and additional N-substituted benzamides
also will be granted.
FIGURE 21 ENTINOSTAT, A BENZAMIDE
CLASS HDAC INHIBITOR 112